The UK and US have secured a major commercial pact that will guarantee no import taxes on British medicine shipments entering the American market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to raise spending on drugs through the NHS. This pledge guarantees that duties on these key exports will be held at zero for a duration of the next three years.
This deal follows earlier warnings to dramatically increase import taxes on branded drug products, with potential rates floated as high as one hundred percent.
"This arrangement with the UK reinforces the international landscape for innovative medicines and introduces much-needed equity to U.S.–U.K. pharmaceutical trade," a statement noted.
Trade Significance
Pharmaceuticals constitute one of the UK's most significant exports to the United States, which is by far the biggest market for leading UK drugmakers.
Statistics show that in the year prior to last September, the UK shipped medicines valued at £11.1bn to the US. This value accounted for a significant portion of British export trade in that span.
"This deal protects work, stimulates capital expenditure and facilitates the UK to establish itself as a global hub for life sciences," a minister stated.
Detailed NHS Changes
The deal entails several notable pledges from the UK:
- Price Threshold Increase: The UK will lift the price threshold at which it judges new medicines to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a aim to raise total public funding on drugs from 0.3% of GDP to 0.6% over the next decade.
- Refund Ceiling: The percentage pharmaceutical firms must return to the NHS to prevent overspending will be capped at fifteen percent. In the past, rebates topped 20%.
Broader Context
The deal comes amid a ongoing tension between the drug companies and the UK government over spending levels and approval rates.
These tensions were heightened by arguments that US consumers were paying a premium for the equivalent treatments than people in the Britain and the EU.
Over the last 18 months, several major manufacturing plans in the UK have been paused or scrapped, while multi-billion-dollar expansions have been announced toward US facilities.
The Science Minister publicly accepted that the NHS must increase expenditure on drugs, noting that its spending on drugs had shrunk as a percentage of its resources over the previous ten-year period.
